Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
This study aims to compare the effect of antiviral therapy with entecavir or tenofovir for
 hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Included
 patients will randomly divide into two groups.
Hepatocellular carcinoma (HCC) is associated with a poor prognosis, and its incidence has
 increased dramatically in many countries. Hepatectomy is a radical therapy for early-stage
 HCC. However, even after radical resection, the prognosis for HCC patients remains
 discouraging because of the high recurrence rate and frequent incidence of intrahepatic
 metastasis. Therefore, preventing HCC recurrence is very important.

 Hepatitis B virus (HBV) infection is the major risk factor for HCC development in China. Some
 retrospective studies have shown that tenofovir or entecavir treatment for HBV-related HCC
 patients can effectively reduce the HCC recurrence rate and increase the survival rate after
 hepatectomy. However, which drug has more efficacy has not been addressed.
Inclusion Criteria:

 -  Underwent open hepatic resection.

 -  Diagnosis of HCC was confirmed by imageological examination with or without AFP.

 -  HBsAg (+).

 -  Child-Pugh A liver function.

 Exclusion Criteria:

 -  Anti-HCV(+)

 -  Diagnosis of HCC was not confirmed by histopathological examination of surgical
 samples after surgery.